Bruker Corporation Reports First Quarter 2009 Results

Bruker Corporation Reports First

Quarter 2009 Results

BILLERICA, Mass., April 30, 2009 (BUSINESS WIRE)

Bruker Corporation (NASDAQ: BRKR) today reported financial results for

the first quarter ended March 31, 2009.

First Quarter 2009 Snapshot

GAAP Revenue decreased 3.3%

GAAP Net Income $8.4

million, EPS $0.05 per diluted share

In the first quarter of 2009, revenue was $230.5 million, a decrease of

3.3% compared to revenue of $238.3 in the first quarter of 2008. Excluding the effects of foreign currency

translation, first quarter 2009 revenue increased by 4.5% year-over-year.

GAAP net income for the first quarter of 2009 was $8.4 million, or

$0.05 per diluted share, compared to a net loss of ($0.8) million, or ($0.00)

per diluted share, in the first quarter of 2008.

Free cash flow for the first quarter of 2009 was $9.2 million, compared

to $8.9 million in the first quarter of 2008.

During the first quarter of 2009, Bruker repaid $20.2 million of debt

and ended the quarter with cash and cash equivalents of $149.9 million, and net

debt of $53.7 million.

Frank Laukien, President and CEO, commented: We are pleased with our

first quarter 2009 results, given the challenges in the marketplace today. During the first quarter, while we saw

softness in our industrial and pharma/biotech orders, we recorded healthy

orders from academic, medical school, government and other non-profit customers,

which typically account for about two-thirds of Bruker s revenue. While we continue to be below our gross

margin and operating margin goals, we have started to see the effects of our

cost-cutting initiatives and we expect to realize further savings in 2009. We continue to rationalize our cost

structure, but we also are investing in new opportunities, and have introduced

a record number of important new products so far in 2009.

Dr. Laukien continued with an update on

the outlook for 2009: While certain industrial and pharma market segments this

year are even more challenging than we had expected, our non-profit,

governmental and other healthcare orders remain strong. For example, we are excited about our

double-digit order growth in life-science mass spectrometry, driven by the compelling

capabilities of our high-performance products.

We also see positive signs as a result of the various international

government stimulus packages, which in our opinion will particularly benefit

high-end research equipment. In Japan,

seen additional orders and revenue, while

elsewhere we have experienced a significant increase in requests for proposals

and assistance with grant writing. We

are hopeful that global stimulus funding for academic, medical and government

research will result in additional business for Bruker in the second half of

Bruker s CFO, Bill Knight, added: The downturn in the global economy is

challenging to navigate and revenue was negatively affected by foreign currency

headwinds in the first quarter. We

continue to explore additional cost savings opportunities, while improving our

operational efficiency through product design, production process improvements

and enhanced balance sheet management.

EARNINGS CONFERENCE CALL

Bruker Corporation will host an

operator-assisted earnings conference call at 10:00 a.m. Eastern Daylight

Time on Thursday, April 30, 2009.

To listen to the webcast, investors can go to http://ir.bruker.com and

click on the live web broadcast symbol.

The webcast will be available through the Company web site for 30

days. Investors can also listen and

participate on the telephone in the US and Canada by calling 888-419-5570, or

+1-617-896-9871 outside the US and Canada.

Investors should refer to the Bruker Earnings Call. A telephone replay of the conference call

will be available one hour after the conference call by dialing 888-286-8010 in

the US and Canada, or +1-617-801-6888 outside the US and Canada, and then

entering replay pass code 71318410. For more information, please visit

Any statements contained in this press release that do not describe

historical facts may constitute forward-looking statements as that term is

defined in the Private Securities Litigation Reform Act of 1995. Any

forward-looking statements contained herein are based on current expectations,

but are subject to a number of risks and uncertainties. The factors that could

cause actual future results to differ materially from current expectations include,

but are not limited to, risks and uncertainties relating to adverse changes in

conditions in the global economy and volatility in the capital markets, the

integration of businesses we have acquired or may acquire in the future,

changing technologies, product development and market acceptance of our

products, the cost and pricing of our products, manufacturing, competition,

dependence on collaborative partners and key suppliers, capital spending and

government funding policies, changes in governmental regulations, intellectual

property rights, litigation, and exposure to foreign currency fluctuations.

These and other factors are identified and described in more detail in our

filings with the SEC, including, without limitation, our annual report on Form 10-K

for the year ended December 31, 2008, our most recent quarterly reports on

Form 10-Q and our current reports on Form 8-K. We disclaim any intent

or obligation to update these forward-looking statements other than as required

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

CONDENSED CONSOLIDATED BALANCE SHEETS